DigestRedComo funciona
Red
/
Empresas
NM
No verificado

NMD Pharma

Sobre qué escribimos

Anuncios brevesBiotecnologíaPublicidad/Marketing/Medios de comunicación/Comunicación

11 Comunicados de prensa

Ver todos los comunicados de prensa
10/03/2026
Biotecnología
Anuncios breves
Publicidad/Marketing/Medios de comunicación/Comunicación
NMD Pharma late breaking oral presentation at the MDA Conference with top-line safety and efficacy data from SYNAPSE-CMT, an exploratory Phase 2a clinical study of ignaseclant in Charcot-Marie-Tooth disease Types 1 & 2
Fuente
NMD Pharma
Editor
GLOBENEWSWIRE
1.00
0
11/02/2026
Biotecnología
Publicidad/Marketing/Medios de comunicación/Comunicación
Anuncios breves
NMD Pharma results from Phase 2a study of ignaseclant in Charcot-Marie-Tooth disease Types 1 and 2 selected for late-breaking oral presentation at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Fuente
NMD Pharma
Editor
GLOBENEWSWIRE
1.00
0
02/02/2026
Biotecnología
Anuncios breves
Publicidad/Marketing/Medios de comunicación/Comunicación
NMD Pharma announces topline results from its Phase 2a study of ignaseclant in Charcot-Marie-Tooth disease Types 1 and 2
Fuente
NMD Pharma
Editor
GLOBENEWSWIRE
1.00
0
02/09/2025
Biotecnología
Publicidad/Marketing/Medios de comunicación/Comunicación
Anuncios breves
NMD Pharma Expands Senior Leadership Team with the Appointment of Ana de Vera as Chief Medical Officer
Fuente
NMD Pharma
Editor
GLOBENEWSWIRE
1.00
0
12/05/2025
Biotecnología
Publicidad/Marketing/Medios de comunicación/Comunicación
Anuncios breves
NMD Pharma to present compelling preclinical data highlighting the potential of ClC-1 ion channel inhibition to improve disease symptoms and progression in MuSK myasthenia gravis at the MGFA International Conference on Myasthenia and Relate
Fuente
NMD Pharma
Editor
GLOBENEWSWIRE
1.00
0
24/03/2025
Biotecnología
Anuncios breves
NMD Pharma presents preclinical data highlighting increased innervation of skeletal muscle with ClC-1 ion channel inhibition treatment in neuromuscular disease model
Fuente
NMD Pharma
Editor
GLOBENEWSWIRE
1.00
0
05/01/2025
Biotecnología
Publicidad/Marketing/Medios de comunicación/Comunicación
Anuncios breves
NMD Pharma Announces FDA Orphan Drug Designation Granted to NMD670 for the Treatment of Patients with Charcot-Marie-Tooth Disease
Fuente
NMD Pharma
Editor
GLOBENEWSWIRE
1.00
0
18/12/2024
Biotecnología
Anuncios breves
NMD Pharma Announces Publication of Phase 1 Clinical Trial Data Evaluating NMD670 in Healthy Volunteers in the Journal Clinical Pharmacology & Therapeutics 
Fuente
NMD Pharma
Editor
GLOBENEWSWIRE
1.00
0
17/12/2024
Biotecnología
Publicidad/Marketing/Medios de comunicación/Comunicación
Anuncios breves
NMD Pharma publishes new data on the role of ClC-1 inhibition in Charcot-Marie-Tooth in the Annals of Clinical and Translational Neurology
Fuente
NMD Pharma
Editor
GLOBENEWSWIRE
1.00
0
17/11/2024
Biotecnología
Publicidad/Marketing/Medios de comunicación/Comunicación
Anuncios breves
NMD Pharma Initiates Phase 2 Study of NMD670 in Patients with Charcot-Marie-Tooth Disease Type 1 and 2
Fuente
NMD Pharma
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0